Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11126523 | 0.90 | POLB (0.43) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL4824917 | 0.85 | POLB (0.51) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL28544889 | 0.83 | POLB (0.53) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL7415249 | 0.81 | MAPK1 (0.47) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL27654581 | 0.76 | MAPT (0.57) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL27523134 | 0.75 | POLB (0.45) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL516898 | 0.74 | ALDH1A1 (0.47) | POLBALDH1A1NPSR1KDM4E | |
| SCHEMBL10710716 | 0.74 | MAPT (0.59) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL7386425 | 0.72 | POLB (0.53) | POLBMAPTMAPK1TSHRALDH1A1 | |
| SCHEMBL1542688 | 0.72 | POLB (0.66) | POLBMAPTMAPK1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545583-B1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MAT US LLC (US) | 2020-05-13 | — | — | EP | claimed |
| US-9187621-B2 | Reflector for light-emitting devices | TICONA LLC (US) | 2015-11-17 | — | — | US | claimed |
| US-8906774-B2 | Methods and compositions for doping silicon substrates with molecular monolayers | DYNALOY, LLC (US) | 2014-12-09 | — | — | US | claimed |
| US-20140299907-A1 | Reflector for Light-Emitting Devices | TICONA LLC (US) | 2014-10-09 | — | — | US | claimed |
| EP-2545583-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | Dynaloy, LLC (US) | 2013-01-16 | — | — | EP | claimed |
| US-20120003826-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MATERIALS US, LLC | 2012-01-05 | — | — | US | claimed |
| WO-2011112546-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | DYNALOY, LLC (US) | 2011-09-15 | — | — | WO | claimed |
| CN-113845754-B | Preparation method of epoxy resin electronic and electric insulating material | 广东博汇新材料科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113817291-B | Carbon fiber vacuum infusion epoxy resin | 广东博汇新材料科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113845754-A | Preparation method of epoxy resin electronic and electric insulating material | 广东博汇新材料科技股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113817291-A | Carbon fiber vacuum infusion epoxy resin | 广东博汇新材料科技股份有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-2545583-B1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MAT US LLC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9567460-B2 | Molded reflectors for light-emitting diode assemblies | TICONA LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010014-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | POLB 2084/4885MAPT 263/4885MAPK1 3185/4885 |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | POLB 3079/4885MAPT 466/4885MAPK1 1563/4885 |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | POLB 2084/4885MAPT 263/4885MAPK1 3185/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | POLB 3079/4885MAPT 466/4885MAPK1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.